Krystal Biotech, Inc. (KRYS) — Fair Value Analysis

Base-case fair value (P50): $317.83 · Current price: $306.29 · Verdict: Fairly Valued

The Verdict on KRYS

KRYSTAL BIOTECH INC (KRYS) is currently assessed as Fairly Valued based on our latest Monte Carlo simulations. With its current market price at $306.29, our median fair value (P50) stands at $317.83. This indicates a projected +3.8% upside to our P50 estimate, suggesting KRYS trades very close to its intrinsic value. While the market often anticipates significant swings, our analysis positions KRYS right within a reasonable valuation range given its underlying fundamentals and the current market conditions. The "average" quality tier assigned to KRYS reflects its operational and financial health relative to its peers, a factor consistently integrated into our fair value calculations.

How KRYS stacks up against peers

Our Monte Carlo simulation for KRYS, which runs thousands of forward-looking scenarios, reveals an "average" quality tier when comparing its operational and financial health against its sector peers. This average standing suggests KRYS possesses a balanced risk-reward profile, neither significantly outperforming nor underperforming its counterparts in key fundamental metrics. The fair value of $317.83 derived from these simulations underscores this equilibrium, positioning KRYS's intrinsic worth only +3.8% above its current trading price of $306.29. For investors, an average quality tier coupled with a near-zero valuation gap implies that while KRYS isn't poised for a dramatic re-rating solely based on its peer comparison, it maintains a stable foundation.

What this means for investors

The determination that KRYS is Fairly Valued, with its current price of $306.29 sitting closely to our median fair value of $317.83, offers a clear signal for investors. The modest +3.8% projected indicates that the market is largely reflecting KRYS's intrinsic worth. For those seeking significant alpha purely from a valuation discrepancy, KRYS may not present the most compelling opportunity at this juncture. However, an "average" quality tier suggests stability, making KRYS a potential consideration for portfolios prioritizing equilibrium over speculative swings. In a downside scenario, the company's average quality could provide some resilience, while a bull case would require a fundamental shift beyond its current intrinsic valuation. For a deeper dive into the full bear/bull distribution and to track KRYS's fair value as new fundamentals are released, sign up for a free FairCurve account.